Permissive Hypercapnia in Extremely Low Birthweight Infants

Conditions

Infant respiratory distress syndrome Respiratory Infant respiratory syndromes

Gentner S, Laube M, Uhlig U, Yang Y, Fuchs HW, Dreyhaupt J, Hummler HD, Uhlig S, Thome UH.

2017-11-212 citations

10.3389/fped.2017.00246

Neurodevelopmental outcomes of extremely low birthweight infants randomised to different PCO<sub>2</sub> targets: the PHELBI follow-up study

Ulrich Thomé, Orsolya Genzel‐Boroviczény, Bettina Bohnhorst, Manuel Schmid, Hans Fuchs et al. (31 authors)

Archives of Disease in Childhood Fetal & Neonatal2017-01-1328 citations

10.1136/archdischild-2016-311581

Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trial.

Thome UH, Genzel-Boroviczeny O, Bohnhorst B, Schmid M, Fuchs H, Rohde O, Avenarius S, Topf HG, Zimmermann A, Faas D, Timme K, Kleinlein B, Buxmann H, Schenk W, Segerer H, Teig N, Gebauer C, Hentschel R, Heckmann M, Schlösser R, Peters J, Rossi R, Rascher W, Böttger R, Seidenberg J, Hansen G, Zernickel M, Alzen G, Dreyhaupt J, Muche R, Hummler HD, PHELBI Study Group.

2015-06-1562 citations

10.1016/s2213-2600(15)00204-0

Interventions

Different PaCO2 target range: Experimental intervention: PaCO2 target range 55 to 65 mmHg (day one to three of life) , 60 to 70 mmHg (day four to six), 65 to 75 mmHg (day seven to 14). Control inter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Extremely low birthweight infants (400 g to 1000 g) requiring mechanical ventilation within 24 hours after birth

Exclusion criteria

Exclusion criteria: Congenital malformations affecting respiratory or cardiac function or requiring surgery

Design outcomes

Primary

Measure	Time frame
1. Bronchopulmonary dysplasia at 36 weeks postmenstrual age 2. Death by intention to treat	—

Secondary

Measure	Time frame
1. Incidence of intracranial haemorrhages 2. Incidence of air leaks 3. Duration of mechanical ventilation 4. Positive pressure support and supplemental oxygen 5. Inflammatory mediators in tracheal aspirates 6. Neurodevelopmental outcome at 18 to 24 months corrected age, per protocol ananlysis of primary outcome	—

Countries

Germany

Outcome results

None listed